Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Learn
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Phosphagenics Completes Pre-Clinical Study of Oxycodone/TPM Technology

20 Feb 2013  |  09:51:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Phosphagenics Further Expands Pain Portfolio

Phosphagenics has completed a pre-clinical study demonstrating that its oxycodone/TPM technology can reduce local pain without the need to deliver oxycodone into the bloodstream. The Company intends to commence clinical trials in Quarter 3 of 2013.

Please click here for full details

See more ASX300 News Announcements